Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 9-Aminocamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.82 |
| ▸ | GLA | P06280 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 9-Aminocamptothecin SCHEMBL29369669 | 1.00 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| Rs-9-Aminocamptothecin SCHEMBL8715088 | 1.00 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| Rs-9-Aminocamptothecin SCHEMBL27705522 | 0.96 | TOP1 (0.92) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL25932523 | 0.92 | TOP1 (0.84) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1006662 | 0.91 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL27561956 | 0.91 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL23270615 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1062768 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL29664993 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A | |
| SCHEMBL1301708 | 0.90 | TOP1 (1.00) | TOP1KDM4ERECQLTDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16636 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026098633-A1 | CONJUGATES AND USES THEREOF | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| WO-2026098715-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING ANTI-CLDN6 ANTIBODY | 智泽童康(广州)生物科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4740956-A1 | PHARMACEUTICAL COMBINATION FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| WO-1995009169-A1 | PROCESS FOR THE PREPARATION OF 9-AMINO CAMPTOTHECIN | PHARMACIA S.P.A. (IT) | 1995-04-06 | — | — | WO | claimed |
| CN-1100426-A | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 1995-03-22 | — | — | CN | claimed |
| WO-1995004736-A1 | PROCESS FOR THE PREPARATION OF 9-AMINO CAMPTOTHECIN | PHARMACIA S.P.A. (IT) | 1995-02-16 | — | — | WO | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0612248-A1 | COMBINATION CHEMOTHERAPY | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-31 | — | — | EP | claimed |
| WO-1993009782-A1 | COMBINATION CHEMOTHERAPY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0436653-A4 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | — | 1992-01-15 | — | — | EP | claimed |
| EP-0436653-A1 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 1991-07-17 | — | — | EP | claimed |
| US-4981968-A | ENZYME INHIBITORS, ANTITUMOR | RESEARCH TRIANGLE INSTITUTE (US) | 1991-01-01 | — | — | US | claimed |
| WO-1990003169-A1 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 1990-04-05 | — | — | WO | claimed |